
CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights to Facilitate Cell Therapy Programs in Oncology
Shots: CRISPR to gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs
[Read More...]